Shares of Zogenix Inc. (NASDAQ: ZGNX), a pharmaceutical company which focuses on treatment related to central nervous disorder and pain, plummeted 46 percent on Monday after the Company revealed that Food and Drug Administration’s advisory committee voted against the application for approval of a pain treatment.
[...]
Recent Comments